Skip to main content
Article
Survival After Liver Transplantation Using Hepatitis C Virus-Positive Donor Allografts: Case-Controlled Analysis of the UNOS Database
Surgery Publications and Presentations
  • Andrew T. Burr, University of Massachusetts Medical School
  • YouFu Li, University of Massachusetts Medical School
  • Jennifer F. Tseng, University of Massachusetts Medical School
  • Reza F. Saidi, University of Massachusetts Medical School
  • Adel Bozorgzadeh, University of Massachusetts Medical School
  • Shimul A. Shah, University of Massachusetts Medical School
UMMS Affiliation
Department of Surgery
Date
3-9-2011
Document Type
Article
Medical Subject Headings
Liver Transplantation; Graft Survival; Hepatitis C
Disciplines
Abstract
BACKGROUND: Numerous reports have documented reduced graft and patient survival after use of hepatitis C (HCV) seropositive allografts in liver transplantation (OLT). We aimed to examine if the use of a HCV+ liver allograft affects patient and graft survivals compared to HCV- donor allografts in a case-controlled analysis of the united network for organ sharing (UNOS) database. METHODS: We examined 63,149 liver transplants (61,905 donors HCV-; 1,244 donors HCV+) from the UNOS standard transplant analysis and research (STAR) file from 1987 to 2007. Donor and recipient demographics and outcomes were collected in which donor HCV serology was complete. A case-controlled cohort from 11 donor and recipient variables comparing donor HCV- and HCV+ allografts (n = 540 in each group) was created using propensity scores with a matching algorithm. Graft and patient survival was estimated using Kaplan-Meier survival curves. RESULTS: Significant differences were evident in the unadjusted cohort between recipients who received HCV+ and HCV- allografts, including HCV+ recipients, donor and recipient age, and model for end-stage liver disease (MELD) exception cases. Use of HCV+ allograft resulted in significantly lower graft survival (8.1 vs. 10.6 years; P = 0.001) and patient survival (10.2 vs. 12.3 years; P = 0.01) after OLT. In the matched cohort, HCV seropositivity had no detrimental effect on the graft (P = 0.57) or patient (P = 0.78) survival after OLT. CONCLUSIONS: This is the first population-based analysis to show that after adjusting for donor and recipient characteristics there was no difference in graft or patient survival with the use of HCV+ donor liver allografts compared to HCV- donor liver allografts.
Rights and Permissions
Citation: World J Surg. 2011 Mar 8. Link to article on publisher's site
Related Resources
Link to Article in PubMed
PubMed ID
21384242
Citation Information
Andrew T. Burr, YouFu Li, Jennifer F. Tseng, Reza F. Saidi, et al.. "Survival After Liver Transplantation Using Hepatitis C Virus-Positive Donor Allografts: Case-Controlled Analysis of the UNOS Database" (2011) ISSN: 0364-2313 (Linking)
Available at: http://works.bepress.com/jennifer_tseng/1/